drugset / Trial / NCT05923177
Molecular Imaging of HER2 Expression in Breast Cancer Using [123I] I-(HE)3-G3
Phase 1
Completed
10 enrolled
Tomsk National Research Medical Center of the Russian Academy of Sciences
NaSingle-groupOpen-labelDiagnostic
Summary
The study should evaluate distribution of \[123I\] I-(HE)3-G3 in patients with primary HER2-positive and HER2-negative breast cancer
Timeline
- Start
- 2023-09-01
- Primary completion
- 2024-09-01
- Completion
- 2024-09-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | HE3-G3 | Diagnostic / imaging agent | 3000 ug | Other |